Cerus Corporation (NASDAQ:CERS) posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03, Briefing.com reports. Cerus Corporation had a negative net margin of 159.35% and a negative return on equity of 142.18%. The firm had revenue of $10.80 million during the quarter, compared to analysts’ expectations of $11.95 million. During the same period last year, the company posted ($0.14) EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year.
Shares of Cerus Corporation (NASDAQ CERS) remained flat at $$3.60 during midday trading on Friday. 509,600 shares of the stock were exchanged, compared to its average volume of 906,881. Cerus Corporation has a twelve month low of $1.93 and a twelve month high of $5.91. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.46 and a current ratio of 3.71.
Several equities research analysts have recently commented on CERS shares. Cowen and Company set a $6.00 target price on shares of Cerus Corporation and gave the stock a “buy” rating in a research report on Thursday, October 5th. Zacks Investment Research raised shares of Cerus Corporation from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Wednesday. BidaskClub raised shares of Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, ValuEngine cut shares of Cerus Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Cerus Corporation has an average rating of “Hold” and an average price target of $6.40.
Cerus Corporation Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.